Surface Ophthalmics

Surface Ophthalmics is a pharmaceutical company developing therapies for ocular diseases. It is advancing three clinical programs: one for chronic dry eye disease (SURF-100), one for acute dry eye disease (SURF-200), and one for pain and inflammation following ophthalmic surgery (SURF-201). These programs utilize Klarity® as a delivery tool, aiming to enhance patient comfort as well as protect and repair the ocular surface. We are led by an experienced and proven management team and board of directors with over 80 years of ophthalmology-related expertise.